Results 131 to 140 of about 6,410,919 (241)

Telangiectasia in Systemic Sclerosis Is a Marker of Increased Disease Morbidity and Mortality: Analyses From the Australian Scleroderma Cohort Study

Australasian Journal of Dermatology, EarlyView.
ABSTRACT This Australian retrospective cohort analysis of 1977 patients investigates and expands on correlates of telangiectasia in systemic sclerosis to determine whether this cutaneous sign is a potential surrogate marker for disease progression and prognosis.
Vivien Wai Yun Lai, Dylan Hansen, Maryam Tabesh, Jessica Fairley, Laura Ross, Nava Ferdowsi, Gene‐Siew Ngian, Diane Apostolopoulos, Joanne Sahhar, Lauren V. Host, Jennifer Walker, Gabor Major, Susanna Proudman, Wendy Stevens, Mandana Nikpour, Amanda M. Saracino   +15 more
wiley   +1 more source

Resveratrol: A novel type of topoisomerase II inhibitor. [PDF]

J Biol Chem, 2017
Lee JH, Wendorff TJ, Berger JM.
europepmc   +1 more source

Chemotherapy resistance and risk stratification in gestational trophoblastic neoplasia: A systematic review and network meta‐analysis

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Higher pretreatment β‐hCG, greater tumor burden, higher FIGO stage/score, and choriocarcinoma were associated with higher chemoresistance risk in gestational trophoblastic neoplasia. In exploratory network analyses, etoposide‐containing regimens showed lower predicted chemoresistance.
Ying‐Ying Xue, Xin‐Yue Yang, Fang‐Yu Chen, Hui‐Ting Yang, Chao Zhang, Jin‐Zhu Yan, Shi‐Shi Wu, Long Wang   +7 more
wiley   +1 more source

The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery. [PDF]

Sci Rep, 2019
Yamamoto K, Kokubun T, Sato K, Akaishi T, Shimazaki A, Nakamura M, Shiga Y, Tsuda S, Omodaka K, Saya H, Nakazawa T.   +10 more
europepmc   +1 more source

Inhibition of late sodium current prevents pathological hyperactivation of calcium/calmodulin‐dependent protein kinase IIδ in a murine model of acute doxorubicin‐related cardiotoxicity

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Doxorubicin (DOX) is a highly effective anthracycline, whose clinical application for cancer is limited by cardiotoxicity. The mechanisms underlying doxorubicin‐induced toxic cardiomyopathy (DICM) involve electrophysiological remodelling with intracellular Na+ overload because of increased late INa and hyperactivation of
Anna‐Lena Feder, Anna‐Maria Pfützenreuter, Lea Maria Funke, Maria Johanna Baier, Daniel Tarnowski, Laura Stengel, Lars Siegfried Maier, Can Martin Sag   +7 more
wiley   +1 more source

Targeting homologous recombination repair to potentiate fluoroquinolone efficacy in Mycobacterium abscessus

mLife, EarlyView.
Shuai Wang, Md Shah Alam, Buhari Yusuf, Jingran Zhang, Ziwen Lu, Xiaofan Zhang, H. M. Adnan Hameed, Mst. Sumaia Khatun, Chunyu Li, Lijie Li, Aleksey A. Vatlin, Aweke M. Belachew, Xirong Tian, Yamin Gao, Cuiting Fang, Rogers P. Zhang, Jun Li, Xinyue Wang, Liqiang Feng, Li Wan, Tianyu Zhang   +20 more
wiley   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer. [PDF]

Invest New Drugs, 2019
Leary A, Le Tourneau C, Varga A, Sablin MP, Gomez-Roca C, Guilbaud N, Petain A, Pavlyuk M, Delord JP.   +8 more
europepmc   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights

British Journal of Pharmacology, EarlyView.
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra, Francesco Niro, Marco Mergiotti, Giovanni Gavatorta, Emilio Hirsch, Alessandra Ghigo   +5 more
wiley   +1 more source